News from cerulean pharma inc A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages.

Latest

Mar 18, 2014, 09:00 ET Cerulean Announces First Patient Dosed in Phase 1b/2 Trial of CRLX101 in Combination with Chemotherapy and Radiation in Neoadjuvant Rectal Cancer

 Cerulean Pharma Inc., a leader in dynamically tumor-targeted nanopharmaceuticals, today announced that the first patient has been dosed in a...


Feb 11, 2014, 09:00 ET Cerulean Announces First Patient Dosed in Phase 2 Clinical Trial of CRLX101 in Combination with Avastin® in Relapsed Ovarian Cancer

 Cerulean Pharma Inc., a leader in dynamically tumor-targeted nanopharmaceuticals, today announced that the first patient has been dosed in an...


Jan 13, 2014, 09:00 ET CRLX101 Meets Primary Endpoint in Phase 2 Clinical Trial in Relapsed Ovarian Cancer

Cerulean Pharma Inc., a leader in dynamically tumor-targeted nanopharmaceuticals, today announced that CRLX101 has achieved its primary efficacy...


Oct 17, 2013, 11:48 ET Cerulean Presentation Selected as a Top Poster at the International Conference on Molecular Targets and Cancer Therapeutics

Cerulean Pharma Inc., a leader in dynamically tumor-targeted nanopharmaceuticals, today announced that a poster on the combinability and efficacy...


Sep 26, 2013, 09:00 ET Combinability of CRLX101 and Avastin® Established in Clinical Trial in Renal Cell Carcinoma

 Cerulean Pharma Inc., a leader in dynamically tumor-targeted nanopharmaceuticals, today announced that the combinability of CRLX101 and...


Sep 09, 2013, 09:00 ET Cerulean Announces Publication of Data from Company's Lead Candidate, CRLX101, in Proceedings of the National Academy of Sciences (PNAS)

 Cerulean Pharma Inc., a leader in dynamically tumor-targeted nanopharmaceuticals, today announced the publication of translational data on...


Apr 04, 2013, 08:00 ET Cerulean Pharma to Present Data on CRLX101's HIF-1a Inhibition at the American Association for Cancer Research Annual Meeting

 Cerulean Pharma Inc., a leader in dynamically tumor-targeted nanopharmaceuticals, today announced that researchers will present both...


Mar 22, 2013, 08:00 ET Cerulean Announces Results from Phase 2b Lung Cancer Trial

 Cerulean Pharma Inc. today announced that a randomized Phase 2b study of its experimental cancer treatment, CRLX101, in patients with...


Jan 07, 2013, 08:00 ET CRLX101 Advances to Second Stage of Phase 2 Clinical Trial in Advanced Ovarian Cancer

Cerulean Pharma Inc., a leader in designing and developing dynamically tumor-targeted nanopharmaceuticals, today announced that CRLX101 has...


Jan 03, 2013, 11:27 ET Cerulean Announces First Patient Dosed in Phase 2 Pharmacodynamic Study of CRLX101 in Advanced Gastric Cancer

 Cerulean Pharma Inc., a leader in developing dynamically tumor-targeted nanopharmaceuticals, today announced that the first patient has been...


Nov 19, 2012, 12:25 ET Cerulean Pharma's Lead Candidate Selected as a "Top 10 Oncology Project to Watch"

 Cerulean Pharma Inc., a leader in developing dynamically tumor-targeted nanopharmaceuticals, today announced that its lead candidate, CRLX101,...


Jul 23, 2012, 09:15 ET Cerulean Announces First Patient Dosed in Phase 2 Study of CRLX101 in Ovarian Cancer

 Cerulean Pharma Inc., a leader in developing dynamically tumor-targeted nanopharmaceuticals, today announced that the first patient has been...


Jul 02, 2012, 09:00 ET Cerulean Completes Enrollment of Randomized Phase 2 Study of CRLX101 in Non-Small Cell Lung Cancer

 Cerulean Pharma Inc., a leader in developing dynamically tumor-targeted nanopharmaceuticals, today announced that it has completed...


Jul 02, 2012, 09:00 ET Cerulean Announces First Patient Dosed in Phase 1b/2a Study of CRLX101 in Combination with Avastin® in Renal Cancer

 Cerulean Pharma Inc., a leader in developing dynamically tumor-targeted nanopharmaceuticals, today announced that the first patient has been...